Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.47 |
| ▸ | PARP1 | P09874 | 7/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807894 | 0.81 | PARP10 (0.53) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL17330414 | 0.79 | HTR2A (0.49) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL15814001 | 0.79 | PARP10 (0.47) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL15830714 | 0.79 | PARP10 (0.47) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL12087017 | 0.79 | PARP1 (0.41) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL15813555 | 0.76 | HTR2C (0.53) | PARP10PARP1F7F3ALDH1A1 | |
| SCHEMBL1613107 | 0.75 | PARP1 (0.54) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL15830724 | 0.72 | PARP10 (0.47) | PARP10PARP1F7F3NPC1 | |
| SCHEMBL793543 | 0.72 | PARP10 (0.47) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL22135686 | 0.72 | PARP10 (0.41) | PARP10PARP1F7F3PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570121-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3521285-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3521285-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190040047-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2019-02-07 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3157915-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2015193765-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193768-A1 | ARYL FUSED LACTAMS AS EZH2 MODULATORS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193768-A1 | ARYL FUSED LACTAMS AS EZH2 MODULATORS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193765-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.